Variation in complement component C1 inhibitor in age-related macular degeneration

J Gibson1, S Hakobyan, A J Cree

  • 1Genetic Epidemiology & Bioinformatics Group, Human Genetics Division, School of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK.

Immunobiology
|August 20, 2011
PubMed

Insights

Plasma C1 inhibitor levels are significantly different in age-related macular degeneration (AMD) patients compared to controls. Genetic variations near the SERPING1 gene influence C1 inhibitor levels, suggesting a role in AMD pathogenesis.

Area of Science:

  • Ophthalmology
  • Immunology
  • Genetics

Background:

  • Age-related macular degeneration (AMD) is a leading cause of vision loss.
  • The complement system, particularly C1 inhibitor (C1inh), plays a role in inflammatory processes.
  • Understanding factors influencing C1inh levels may provide insights into AMD.

Purpose of the Study:

  • To investigate plasma C1 inhibitor (C1inh) levels in patients with age-related macular degeneration (AMD) and healthy controls.
  • To explore associations between C1inh levels and AMD, demographic factors, and genetic variations in the SERPING1 gene.

Main Methods:

  • Plasma C1inh protein levels were measured using rate nephelometry in 391 AMD cases and 370 controls.
  • Multivariate analysis was employed to assess relationships between C1inh levels and age, gender, smoking status, AMD status, and SERPING1 gene variants.
  • Single nucleotide polymorphism (SNP) rs2649663 near the SERPING1 gene was analyzed for its association with C1inh levels.

Main Results:

  • Significantly higher C1inh levels were observed in AMD cases compared to controls (p=2.340E-6).
  • C1inh levels were also significantly associated with smoking status (p=1.022E-4) and gender (p=1.661E-7).
  • AMD status remained a significant factor after adjusting for gender and smoking. A SNP (rs2649663) 5' of SERPING1 was associated with C1inh levels but not AMD.

Conclusions:

  • Plasma C1inh levels are significantly elevated in individuals with AMD.
  • Genetic variations in the promoter region of the SERPING1 gene may influence C1inh expression and potentially contribute to AMD development.
  • Further research is warranted to elucidate the precise role of C1inh in AMD pathogenesis.

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...